Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7405591 | 0.98 | GBA1 (0.53) | GBA1SLC6A4HTR6CNR1KDM1A | |
| SCHEMBL30962130 | 0.90 | EED (0.43) | GBA1SLC6A4HTR6CNR1 | |
| SCHEMBL21358942 | 0.90 | EED (0.43) | GBA1SLC6A4HTR6CNR1 | |
| SCHEMBL4292162 | 0.87 | CNR1 (0.52) | CNR1KDM1AALDH1A1HTT | |
| SCHEMBL1874417 | 0.85 | GBA1 (0.50) | GBA1SLC6A4HTR6ACP1DPP4 | |
| SCHEMBL16365283 | 0.85 | GBA1 (0.50) | GBA1SLC6A4CNR1ACP1PRMT5 | |
| SCHEMBL22266049 | 0.85 | GBA1 (0.50) | GBA1SLC6A4ACP1PRMT5WDR77 | |
| SCHEMBL5215583 | 0.85 | GBA1 (0.50) | GBA1SLC6A4PRMT5WDR77TLR7 | |
| SCHEMBL14747890 | 0.85 | GBA1 (0.50) | GBA1SLC6A4HTR6PRMT5WDR77 | |
| Hydrochloric Acid SCHEMBL19639936 | 0.83 | GBA1 (0.49) | GBA1SLC6A4CNR1ACP1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| US-12268687-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-08 | — | — | US | disclosed |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-12098146-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-24 | — | — | US | disclosed |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-113906019-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| EP-1771429-A1 | NEW BENZOYL UREA DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010966-A1 | NEW BENZOYL UREA DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
| EP-0934932-A1 | QUINOLINE DERIVATIVES AND PSYCHOTROPIC AGENT | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | GBA1 2652/4885SLC6A4 2513/4885HTR6 1450/4885 |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | GBA1 173/4885SLC6A4 451/4885HTR6 1317/4885 |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | GBA1 4362/4885SLC6A4 570/4885HTR6 462/4885 |
| US-12268687-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | GBA1 173/4885SLC6A4 451/4885HTR6 1317/4885 |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | MAOA, DRD2, MAOB | GBA1 1662/4885SLC6A4 23/4885HTR6 22/4885 |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | GBA1 173/4885SLC6A4 451/4885HTR6 1317/4885 |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | GBA1 173/4885SLC6A4 451/4885HTR6 1317/4885 |
| US-12098146-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | GBA1 173/4885SLC6A4 451/4885HTR6 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.